The present disclosure encompasses the protein BAH, and two cleavage productsthereof, Vstat120 and Vstat40. The disclosure also describes the use of BAH,and two cleavage products thereof, Vstat120 and Vstat40, as an anti-angiogenicand anti- tumorigenic therapy for gliomas as well as its other types of cancerand conditions involving aberrant angiogenesis. One aspect of the disclosuretherefore provides a polypeptide, derived from the protein BAH, comprisingan integrin binding domain and a thrombospondin type 1 repeat. Another aspectof the disclosure provides methods of inhibiting the formation of a tumor sustainedor disseminated by angiogenesis, comprising: contacting a developing tumorwith one of the polypeptides derived from the protein BAM whereupon angiogenesisis inhibited, and thereby inhibiting the formation of the tumor. Another aspectof the disclosure is pharmaceutical compositions comprising a Vstat120 andVstat40 polypeptide, or variants thereof, an at least one carrier for deliveryto an animal or human patient.
